Gilead Sciences, Inc.

Portola Pharmaceuticals, Inc.

Virobay, Inc.

Amygdala Neurosciences, Inc.

Alexion Pharmaceuticals, Inc.

Quest Diagnostics Investments, Inc.

Gilead Pharmasset LLC

Chandrasekar Venkataramani

Juan A Guerrero

Jeff A Zablocki

John O Link

James G Taylor

Richard L Mackman

Michael Graupe

William John Watkins

Xiaofen Li

Devan Naduthambi

Elfatih O Elzein

Barton W Phillips

Dmitry Koltun

Anjali Pandey

Yonghong Song

Rao V Kalla

Qing Xu

Zhaozhong Jon Jia

Thao Perry

Tetsuya Kobayashi

Britton Kenneth Corkey

Robert H Jiang

Peiyuan Wang

Darryl Kato

Gregory Notte

Lan Jiang

Scott E Lazerwith

Hong Yang

Peter A Blomgren

Scott A Mitchell

Michael L Mitchell

Zhongdong Zhao

Kevin S Currie

Hyung-Jung Pyun

Jeffrey E Kropf

Choung U Kim

Manoj C Desai

Aesop Cho

Zheng-Yu Yang

Sheila M Zipfel

Jianjun Xu

Seung H Lee

Jeromy J Cottell

Elizabeth M Bacon

Lianhong Xu

Thorsten A Kirschberg

Scott D Schroeder

Winston C Tse

Eda Y Canales

Jay P Parrish

Michael O'Neil Hanrahan Clarke

Shawn M Bauer

Hongyan Guo

Zhimin Du

Eric Q Parkhill

Wolin Huang

Mukund Mehrotra

Ruben Martinez

Jack W Rose

John Edward Knox, Jr

Jonathan William Medley

Carina E Cannizzaro

Joshua A Kaplan

David W Lin

Vickie H Tsui

Hang Chu

Robert G Strickley

Anna E Hurtley

Brian Kane

Julie Farand

Kin Shing Yang

Neil H Squires

Jennifer R Lo

Musong Kim

Rhiannon Thomas-Tran

Lawrence S Melvin, Jr

Aaron C Schmitt

Jiayao Li

Samuel E Metobo

Michael Sangi

Haolun Jin

Randall W Vivian

Adam James Schrier

Suet Chung Yeung

Ashley Anne Katana

Kirk L Stevens

Qi Liu

Ryan McFadden

Julian Andrew Codelli

Jayaraman Chandrasekhar

Gayatri Balan

Gregg M Schwarzwalder

Michael R Mish

Jie Xu

Evan S Krygowski

Evangelos Aktoudianakis

Scott Preston Simonovich

David Dornan

Chien-Hung Chou

The present disclosure relates generally to compounds that bind to and act as degraders of an IKAROS Family Zinc Finger (IKZF) protein, such as IKZF2 (Helios) and/or IKZF4 (Eos). The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding and degradation of an IKZF protein, such as IKZF2 and/or IKZF4, including cancer.

IKAROS Zinc Finger Family degraders and uses thereof

The present disclosure generally relates to compounds of Formula (1) and pharmaceutical compositions that may be used in methods of treating cancer.

MCL1 inhibitors

The present disclosure generally relates to compounds and pharmaceutical compositions that may be used in methods of treating cancer.

MCL-1 inhibitors

The present disclosure relates generally to compounds that bind to Lysophosphatidic Acid Receptor 1 (LPAR1) and act as antagonists of LPAR1. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of LPAR1, including fibrosis and liver diseases such as non-alcoholic steatohepatitis (NASH).

LPA receptor antagonists and uses thereof

The present disclosure relates to compounds that bind to and act as degraders of an IKAROS Family Zinc Finger (IKZF) protein, such as IKZF2 (Helios). The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding and degradation of an IKZF protein, such as IKZF2, including cancer.

IKAROS zinc finger family degraders and uses thereof

Triazole carbamate pyridyl sulfonamides as LPA receptor antagonists and uses thereof

The present disclosure generally relates to methods of treating cancer by administering an MCL-1 inhibitor and an anticancer agent.

Combination MCL-1 inhibitors with anti-cancer agents

The present disclosure generally relates to methods of treating or preventing cancer by administering an MCL-1 inhibitor and an antibody-drug conjugate, and optionally one or more additional anti-cancer agents. In particular, the MCL-1 inhibitor can be a compound of formula (I), (II) or (III), or compound A. The antibody-drug conjugate can comprises an anti-Trop-2 antibody and an anti-cancer agent (e.g., SN-38). The combination therapy for treating cancer can have synergistic effect.

Combination MCL-1 inhibitors with anti-body drug conjugates

The present disclosure relates generally to compounds that bind to Lysophosphatidic Acid Receptor 1 (LPAR1) and act as antagonists of LPAR1. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of LPAR1, including fibrosis and liver diseases such as non alcoholic steatohepatitis (NASH).

The present disclosure generally relates to compounds of Formula (I) and pharmaceutical compositions that may be used in methods of treating cancer. 

The present disclosure relates generally to compounds that bind to Lysophosphatidic Acid Receptor 1 (LPAR1) and act as antagonists of LPAR1. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of LPAR1, including fibrosis and liver diseases such as non-alcoholic steatohepatitis (NASH), interstitial lung disease (ILD), or chronic kidney disease (CKD).

The present invention is directed to methods of treating multiple myeloma by administering a compound of Formula (I) or pharmaceutically acceptable salt thereof.

Inhibitors of protein kinases

Growing community of inventors

Redwood City, CA, United States of America

Chandrasekar Venkataramani